下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Progyny (NASDAQ:PGNY) Issues Q3 2022 Earnings Guidance
Progyny(纳斯达克股票代码:PGNY)发布2022年第三季度收益指引

Financial News Live ·  {{timeTz}}

Progyny (NASDAQ:PGNY – Get Rating) issued an update on its third quarter 2022 earnings guidance on Thursday morning. The company provided EPS guidance of $0.02-$0.03 for the period, compared to the consensus EPS estimate of $0.06. The company issued revenue guidance of $190.00 million-$197.00 million, compared to the consensus revenue estimate of $192.00 million. Progyny also updated its FY 2022 guidance to $0.14-$0.19 EPS.

周四上午,普罗吉尼(纳斯达克代码:PGNY-GET Rating)发布了2022年第三季度收益指引的最新数据。该公司为该季度提供的每股收益指引为0.02至0.03美元,而市场普遍预期的每股收益为0.06美元。该公司发布的营收指引为1.9亿至1.97亿美元,而市场普遍预期的营收为1.92亿美元。Progyny还将其2022财年每股收益指引更新为0.14-0.19美元。

Progyny Stock Performance

Progyny股票表现

NASDAQ PGNY traded up $11.38 on Friday, hitting $41.15. 3,469,925 shares of the stock were exchanged, compared to its average volume of 684,594. The firm has a market capitalization of $3.78 billion, a P/E ratio of 89.46, a P/E/G ratio of 21.71 and a beta of 1.85. The stock has a fifty day moving average price of $30.23 and a two-hundred day moving average price of $37.32. Progyny has a 52-week low of $25.67 and a 52-week high of $68.32.

上周五,纳斯达克PGNY股价上涨11.38美元,至41.15美元。该股成交3469,925股,而平均成交量为684,594股。该公司的市值为37.8亿美元,市盈率为89.46,市盈率为21.71,贝塔系数为1.85。该股的50日移动均线价格为30.23美元,200日移动均线价格为37.32美元。Progyny的52周低点为25.67美元,52周高点为68.32美元。

Get
到达
Progyny
孕期
alerts:
警报:

Progyny (NASDAQ:PGNY – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.04. Progyny had a net margin of 7.39% and a return on equity of 18.11%. The business had revenue of $195.00 million during the quarter, compared to analyst estimates of $190.51 million. During the same period last year, the business earned $0.19 EPS. Progyny's revenue was up 51.5% compared to the same quarter last year. Sell-side analysts expect that Progyny will post 0.17 earnings per share for the current fiscal year.

纳斯达克(纳斯达克代码:PGNY-GET Rating)上一次发布季度收益数据是在8月4日星期四。该公司公布本季度每股收益为0.09美元,比分析师普遍预期的0.05美元高出0.04美元。Progyny的净利润率为7.39%,股本回报率为18.11%。该业务本季度营收为1.95亿美元,而分析师预期为1.9051亿美元。去年同期,该业务每股收益为0.19美元。与去年同期相比,Progyny的收入增长了51.5%。卖方分析师预计,Progyny本财年每股收益将为0.17美元。

Insider Buying and Selling

内幕买卖

In related news, Director Norman Payson sold 6,618 shares of the firm's stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $33.45, for a total value of $221,372.10. Following the completion of the sale, the director now directly owns 490,828 shares in the company, valued at approximately $16,418,196.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Chairman David J. Schlanger sold 1,452 shares of the company's stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $31.21, for a total transaction of $45,316.92. Following the completion of the transaction, the chairman now owns 82,548 shares in the company, valued at approximately $2,576,323.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Norman Payson sold 6,618 shares of Progyny stock in a transaction that occurred on Wednesday, May 11th. The stock was sold at an average price of $33.45, for a total transaction of $221,372.10. Following the completion of the transaction, the director now directly owns 490,828 shares in the company, valued at $16,418,196.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,240 shares of company stock worth $1,291,601. 14.00% of the stock is owned by company insiders.
在相关新闻中,董事诺曼·佩森在一笔日期为5月11日(星期三)的交易中出售了6618股该公司股票。这些股票的平均价格为33.45美元,总价值为221,372.10美元。出售完成后,董事现在直接拥有该公司490,828股,价值约16,418,196.60美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,这份文件可以在美国证券交易委员会的网站上找到。在相关新闻中,董事长大卫·J·施兰格在一笔日期为6月27日星期一的交易中出售了1,452股公司股票。这些股票以31.21美元的平均价格出售,总成交金额为45316.92美元。交易完成后,董事长现在拥有该公司82,548股,价值约2,576,323.08美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过美国证券交易委员会网站访问该文件。此外,在5月11日(星期三)的一笔交易中,董事诺曼·佩森出售了6,618股Progyny股票。该股以33.45美元的平均价格出售,总成交金额为221,372.10美元。交易完成后,董事现在直接拥有该公司490,828股,价值16,418,196.60美元。此次拍卖的披露信息可在此处找到。在上个季度,内部人士出售了41,240股公司股票,价值1,291,601美元。14.00%的股份由公司内部人士持有。

Institutional Inflows and Outflows

机构资金流入和流出

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Yousif Capital Management LLC boosted its stake in Progyny by 1.1% during the first quarter. Yousif Capital Management LLC now owns 37,264 shares of the company's stock valued at $1,915,000 after buying an additional 392 shares during the last quarter. Captrust Financial Advisors boosted its position in shares of Progyny by 25.0% during the first quarter. Captrust Financial Advisors now owns 2,091 shares of the company's stock valued at $107,000 after purchasing an additional 418 shares in the last quarter. Prudential Financial Inc. boosted its position in shares of Progyny by 6.4% in the 1st quarter. Prudential Financial Inc. now owns 10,603 shares of the company's stock worth $545,000 after purchasing an additional 637 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Progyny during the first quarter worth about $62,000. Finally, Parkside Financial Bank & Trust acquired a new stake in Progyny during the first quarter valued at approximately $70,000. 82.51% of the stock is owned by hedge funds and other institutional investors.

对冲基金和其他机构投资者最近买卖了该股的股票。Yousif Capital Management LLC在第一季度将其在Progyny的持股增加了1.1%。Yousif Capital Management LLC现在拥有37,264股该公司股票,价值1,915,000美元,上个季度又购买了392股。CapTrust Financial Advisors在第一季度将其在Progyny股票的头寸增加了25.0%。CapTrust Financial Advisors在上个季度额外购买了418股后,现在拥有2,091股该公司股票,价值10.7万美元。保诚金融第一季度将其在Progyny股票的持仓增加了6.4%。保诚金融现在持有10,603股该公司股票,价值545,000美元,该公司在上个季度又购买了637股。Lazard Asset Management LLC在第一季度收购了Progyny价值约62,000美元的新股。最后,Parkside Financial Bank&Trust在第一季度收购了Progyny的新股份,价值约为7万美元。82.51%的股票由对冲基金和其他机构投资者持有。

About Progyny

关于Progyny

(Get Rating)

(获取评级)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Progyny,Inc.是一家福利管理公司,专门为美国雇主提供生育和家庭建设福利解决方案。其生育福利解决方案包括差异化福利计划设计、个性化礼宾式会员支持服务和有选择的生育专家网络。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Progyny (PGNY)
  • MarketBeat: Week in Review 8/1 – 8/5
  • How to Use High Beta Stocks to Maximize Your Investing Profits
  • Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
  • Beyond Meat Is Not Beyond Hope, And It's Cheap
  • Why Apple Could Be At All-Time Highs By Year End
  • 免费获取StockNews.com关于Progyny的研究报告(PGNY)
  • MarketBeat:回顾中的一周8/1-8/5
  • 如何利用高贝塔系数股票最大化你的投资利润
  • 克罗诺斯集团(Cronos Group Inc.)营收上升,是时候收购了吗?
  • Beyond Meat不是没有希望,而且它很便宜
  • 苹果为何可能在年底创下历史新高

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.

接受Progyny Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Progyny和相关公司的最新新闻和分析师评级的每日简要摘要。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。

回到顶部